Icotinib Application Scope

It is indicated for the treatment of patients with advanced, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-sensitive mutations.
It can be used as:

First-line therapy for patients with EGFR-mutant NSCLC
Second-line therapy for patients who have progressed after chemotherapy
Maintenance therapy for those who have achieved disease control after initial treatment
conmana icotinib

Icotinib Characteristics

Ingredients: Each tablet contains 125 mg of Icotinib Hydrochloride as the active ingredient.
Properties: White or off-white, film-coated tablets.
Packaging Specification: 125 mg × 21 tablets per box, designed for one-week dosing cycles.
Storage: Store at temperatures below 25 °C in a dry place, protected from moisture and light.
Expiry Date: 24 months from the date of manufacture (see package for exact date).
Executive Standard: In compliance with the National Drug Standard of China (YBHxxxxxxx).
Approval Number: Chinese NMPA Approval No.: H20110077
Date of Revision: Refer to the most recent official prescribing information.
Manufacturer: Beta Pharma (China) Co., Ltd.

Guidelines for the Use of Conmana

Dosage and Administration:
- Recommended Dose: 125 mg three times daily (total daily dose: 375 mg).
- Administration: Administer orally, with or without food. Swallow tablets whole with water.
- Missed Dose: Take the missed dose as soon as remembered, unless it is almost time for the next scheduled dose. Do not double-dose.
Adverse Reactions:
- Common Adverse Reactions:
  - Skin rash, pruritus
  - Diarrhea
  - Dry skin
  - Elevated liver enzymes (ALT/AST)
  - Fatigue
- Serious Adverse Reactions:
  - Interstitial lung disease (rare but potentially fatal)
  - Severe hepatic impairment
  - Severe dermatological reactions
Contraindications:
- Known hypersensitivity to it or any excipient
- Use with caution in patients with severe hepatic or renal impairment.
Precautions:
- Monitor liver function tests periodically during treatment.
- Discontinue icotinib if symptoms of interstitial lung disease (cough, dyspnea, fever) develop.
- Use with caution in patients with pre-existing lung disorders.
- Advise patients to avoid prolonged sun exposure and use sunscreen to reduce skin rash.

Icotinib Interactions

CYP3A4 Inducers: (rifampin, phenytoin, carbamazepine) may reduce the plasma concentration of icotinib and decrease efficacy
CYP3A4 Inhibitors: (ketoconazole, itraconazole, clarithromycin) may increase icotinib exposure, requiring close monitoring
Proton Pump Inhibitors / Antacids: may affect absorption; administer icotinib at least several hours apart if needed

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.